David Chandiwana

Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2

Sunil Verma, Joyce O’Shaughnessy, Howard A. Burris et al. · Breast Cancer Research and Treatment · 2018 · 93 citations · Full text

Medicine, Oncology, Pharmacology +16

Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)

Nadia Harbeck, Fábio Franke, Rafael Villanueva-Vázquez et al. · Therapeutic Advances in Medical Oncology · 2020 · 60 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study

Peter A. Fasching, J. Thaddeus Beck, Arlene Chan et al. · The Breast · 2020 · 38 citations · Full text

Medicine, Oncology, Pharmacology +15

Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2–, <i>PIK3CA</i>-Mutated Breast Cancer

Stuart Turner, Stephen Chia, Hemanth Kanakamedala et al. · The Oncologist · 2021 · 38 citations · Full text

Medicine, Oncology, Pharmacology +14

Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom

Jordan Amdahl, Jose Diaz, Arati Sharma et al. · PLoS ONE · 2017 · 32 citations · Full text

Medicine, Oncology, Pharmacoeconomics +14